Karly A. Stanley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karly A. Stanley has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Gennie L. Parkman
Department of Zoology, Weber State University, Ogden, Utah 84408, USA
19 shared publications - Matthew W. VanBrocklin
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
19 shared publications - Sheri L. Holmen
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
19 shared publications - David A. Kircher
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA
18 shared publications - Martin McMahon
Huntsman Cancer Institute
18 shared publications - Tursun Turapov
Division of Gastroenterology, Hepatology, and Nutrition, University of Utah School of Medicine, Salt Lake City, UT
18 shared publications
Latest Publications
- Open Access
Focal Adhesion Kinase Signaling Promotes Metastasis of BRAFV600E-Driven Melanoma
Background/Objectives: Despite several FDA-approved therapies, metastatic melanoma remains a major clinical challenge, particularly in patients with brain metastases, which are associated with treatment failure and melanoma-related mortality. The molecular mechanisms underlying the development of melanoma brain metastasis remain incompletely understood. Methods: Building on our prior discovery that AKT1 activates focal adhesion kinase (FAK), we analyzed clinical-genomic data to evaluate the association between PTK2 mRNA expression and overall survival in melanoma cohorts. For functional assessment, we used complementary in vitro and in vivo approaches to investigate the effects of FAK overexpression, FAK activation, FAK kinase-dependence, and expression of FAK-related non-kinase (FRNK) on cell proliferation, migration, and invasion. Complementary syngeneic and genetically engineered mouse models were used to assess tumor growth and metastatic dissemination. Results: High PTK2 (FAK) mRNA expression was associated with shorter overall survival in melanoma cohorts, including patients with BRAF-mutant melanoma treated with BRAF and MEK inhibitors. Pharmacologic MEK inhibition increased FAK phosphorylation at the activating Y397 site, suggesting a potential compensatory response to MAPK pathway inhibition. Functional studies implicated FAK expression and signaling in melanoma cell migration, invasion, tumor growth, and metastatic dissemination. Expression of a kinase dead FAK mutant markedly impaired tumor growth and metastasis in vivo. Conclusions: These findings implicate FAK signaling in melanoma progression and metastatic dissemination. The observed effects of FAK mutants support the further investigation of FAK kinase activity as a therapeutic target. In addition, increased FAK Y397 phosphorylation following MEK inhibition provides a rationale for evaluating combined FAK and MAPK pathway inhibition clinically in patients with advanced melanoma.
Open AccessFocal Adhesion Kinase Signaling Promotes Metastasis of BRAFV600E-Driven Melanoma
Background/Objectives: Despite several FDA-approved therapies, metastatic melanoma remains a major clinical challenge, particularly in patients with brain metastases, which are associated with treatment failure and melanoma-related mortality. The molecular mechanisms underlying the development of melanoma brain metastasis remain incompletely understood. Methods: Building on our prior discovery that AKT1 activates focal adhesion kinase (FAK), we analyzed clinical-genomic data to evaluate the association between PTK2 mRNA expression and overall survival in melanoma cohorts. For functional assessment, we used complementary in vitro and in vivo approaches to investigate the effects of FAK overexpression, FAK activation, FAK kinase-dependence, and expression of FAK-related non-kinase (FRNK) on cell proliferation, migration, and invasion. Complementary syngeneic and genetically engineered mouse models were used to assess tumor growth and metastatic dissemination. Results: High PTK2 (FAK) mRNA expression was associated with shorter overall survival in melanoma cohorts, including patients with BRAF-mutant melanoma treated with BRAF and MEK inhibitors. Pharmacologic MEK inhibition increased FAK phosphorylation at the activating Y397 site, suggesting a potential compensatory response to MAPK pathway inhibition. Functional studies implicated FAK expression and signaling in melanoma cell migration, invasion, tumor growth, and metastatic dissemination. Expression of a kinase dead FAK mutant markedly impaired tumor growth and metastasis in vivo. Conclusions: These findings implicate FAK signaling in melanoma progression and metastatic dissemination. The observed effects of FAK mutants support the further investigation of FAK kinase activity as a therapeutic target. In addition, increased FAK Y397 phosphorylation following MEK inhibition provides a rationale for evaluating combined FAK and MAPK pathway inhibition clinically in patients with advanced melanoma.
- Open Access
Focal adhesion kinase promotes metastasis in BRAF-mutant melanoma
Despite the availability of several FDA-approved therapies, metastatic melanoma remains a significant clinical challenge, particularly for patients with brain metastases, which frequently represent the site of treatment failure and a major cause of melanoma-related mortality. Melanoma exhibits a strong propensity to metastasize to the brain, yet the molecular mechanisms driving this lethal progression remain incompletely understood, limiting the development of effective treatment options. Building on our prior discovery that focal adhesion kinase (FAK) is a key mediator of AKT1-driven brain metastasis, we sought to validate the role of FAK in melanoma progression and metastatic dissemination. Using complementary autochthonous and syngeneic mouse models of BRAF-mutant melanoma, we evaluated the impact of FAK expression on overall survival, primary tumor growth, and metastasis. Through the generation of targeted FAK mutants, we distinguished kinase-dependent from kinase-independent functions and demonstrate that FAK promotes melanoma metastasis in a kinase-dependent manner. Furthermore, we establish that FAK functions downstream of PTEN to drive metastatic progression. Collectively, these findings support the therapeutic potential of FAK inhibition, either alone or in combination with existing treatments, to more effectively combat metastatic melanoma and inform the development of emerging FAK-targeted therapies.
Open AccessFocal adhesion kinase promotes metastasis in BRAF-mutant melanoma
Despite the availability of several FDA-approved therapies, metastatic melanoma remains a significant clinical challenge, particularly for patients with brain metastases, which frequently represent the site of treatment failure and a major cause of melanoma-related mortality. Melanoma exhibits a strong propensity to metastasize to the brain, yet the molecular mechanisms driving this lethal progression remain incompletely understood, limiting the development of effective treatment options. Building on our prior discovery that focal adhesion kinase (FAK) is a key mediator of AKT1-driven brain metastasis, we sought to validate the role of FAK in melanoma progression and metastatic dissemination. Using complementary autochthonous and syngeneic mouse models of BRAF-mutant melanoma, we evaluated the impact of FAK expression on overall survival, primary tumor growth, and metastasis. Through the generation of targeted FAK mutants, we distinguished kinase-dependent from kinase-independent functions and demonstrate that FAK promotes melanoma metastasis in a kinase-dependent manner. Furthermore, we establish that FAK functions downstream of PTEN to drive metastatic progression. Collectively, these findings support the therapeutic potential of FAK inhibition, either alone or in combination with existing treatments, to more effectively combat metastatic melanoma and inform the development of emerging FAK-targeted therapies.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S6 shows that INY-03-041 leads to a substantial effect on melanoma cell proliferation but it is not as potent as siAKT1-3. A, Cell confluency assay of MTG001 and MTG004 cell lines treated with DMSO control, GDC0068 (1µM), INY-03-041 (1µM), GDC0941 (1µM), Lenalidomide (1µM), or siAKT1-3 (50nM). Treatment with INY-03-041 led to decreased cell proliferation (P < 0.0001 in each cell line), but did not lead to cell death, similar to siAKT1-3 in MTG001 and MTG004. Lenalidomide, a recruiter of the E3 ubiquitin ligase Cereblon, conjugated to GDC0068 to form INY-03-041, was used as a negative control for the off-target effects of INY-03-041. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of cell lysates treated with the DMSO control, MK2206 (2.5µM), GDC0068 (1µM), INY-03-041 (500nM), GSK0394 (3µM), GDC0941 (1µM), BYL719 (1µM), siAKT1-3 (50nM) at 22 h, and siAKT1-3 (50nM) for 24 h revealed complete knockdown of P-AKT (Ser473) and total AKT by siAKT1-3 at 24 h, as well as knockdown of P-PRAS40, P-S6 kinase, and P-4EBP1. INY-03-041 displayed a 77% reduction in total AKT compared to the 89% reduction by siAKT1-3. C, Time-course immunoblotting of cell lysates treated with varying concentrations of INY-03-041 demonstrated an incomplete total protein knockdown of individual AKT paralogs. D, Densitometry quantification of time-course immunoblotting found in C.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S6 shows that INY-03-041 leads to a substantial effect on melanoma cell proliferation but it is not as potent as siAKT1-3. A, Cell confluency assay of MTG001 and MTG004 cell lines treated with DMSO control, GDC0068 (1µM), INY-03-041 (1µM), GDC0941 (1µM), Lenalidomide (1µM), or siAKT1-3 (50nM). Treatment with INY-03-041 led to decreased cell proliferation (P < 0.0001 in each cell line), but did not lead to cell death, similar to siAKT1-3 in MTG001 and MTG004. Lenalidomide, a recruiter of the E3 ubiquitin ligase Cereblon, conjugated to GDC0068 to form INY-03-041, was used as a negative control for the off-target effects of INY-03-041. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of cell lysates treated with the DMSO control, MK2206 (2.5µM), GDC0068 (1µM), INY-03-041 (500nM), GSK0394 (3µM), GDC0941 (1µM), BYL719 (1µM), siAKT1-3 (50nM) at 22 h, and siAKT1-3 (50nM) for 24 h revealed complete knockdown of P-AKT (Ser473) and total AKT by siAKT1-3 at 24 h, as well as knockdown of P-PRAS40, P-S6 kinase, and P-4EBP1. INY-03-041 displayed a 77% reduction in total AKT compared to the 89% reduction by siAKT1-3. C, Time-course immunoblotting of cell lysates treated with varying concentrations of INY-03-041 demonstrated an incomplete total protein knockdown of individual AKT paralogs. D, Densitometry quantification of time-course immunoblotting found in C.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S4 demonstrates that siAKT1-3 is specific for human AKT. A, The cell confluency assay of YUMM1.1 mouse melanoma cells under genetic inhibition demonstrated no effect on cell death with siAKT1, siAKT2, siAKT3, or any combination. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of YUMM1.1 cells treated with siCtrl vs siAKT1-3. No knockdown of P-AKT (Ser473) or P-PRAS40 (T246) indicated the specificity of the siRNAs for human AKT.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S4 demonstrates that siAKT1-3 is specific for human AKT. A, The cell confluency assay of YUMM1.1 mouse melanoma cells under genetic inhibition demonstrated no effect on cell death with siAKT1, siAKT2, siAKT3, or any combination. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of YUMM1.1 cells treated with siCtrl vs siAKT1-3. No knockdown of P-AKT (Ser473) or P-PRAS40 (T246) indicated the specificity of the siRNAs for human AKT.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S6 shows that INY-03-041 leads to a substantial effect on melanoma cell proliferation but it is not as potent as siAKT1-3. A, Cell confluency assay of MTG001 and MTG004 cell lines treated with DMSO control, GDC0068 (1µM), INY-03-041 (1µM), GDC0941 (1µM), Lenalidomide (1µM), or siAKT1-3 (50nM). Treatment with INY-03-041 led to decreased cell proliferation (P < 0.0001 in each cell line), but did not lead to cell death, similar to siAKT1-3 in MTG001 and MTG004. Lenalidomide, a recruiter of the E3 ubiquitin ligase Cereblon, conjugated to GDC0068 to form INY-03-041, was used as a negative control for the off-target effects of INY-03-041. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of cell lysates treated with the DMSO control, MK2206 (2.5µM), GDC0068 (1µM), INY-03-041 (500nM), GSK0394 (3µM), GDC0941 (1µM), BYL719 (1µM), siAKT1-3 (50nM) at 22 h, and siAKT1-3 (50nM) for 24 h revealed complete knockdown of P-AKT (Ser473) and total AKT by siAKT1-3 at 24 h, as well as knockdown of P-PRAS40, P-S6 kinase, and P-4EBP1. INY-03-041 displayed a 77% reduction in total AKT compared to the 89% reduction by siAKT1-3. C, Time-course immunoblotting of cell lysates treated with varying concentrations of INY-03-041 demonstrated an incomplete total protein knockdown of individual AKT paralogs. D, Densitometry quantification of time-course immunoblotting found in C.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S6 shows that INY-03-041 leads to a substantial effect on melanoma cell proliferation but it is not as potent as siAKT1-3. A, Cell confluency assay of MTG001 and MTG004 cell lines treated with DMSO control, GDC0068 (1µM), INY-03-041 (1µM), GDC0941 (1µM), Lenalidomide (1µM), or siAKT1-3 (50nM). Treatment with INY-03-041 led to decreased cell proliferation (P < 0.0001 in each cell line), but did not lead to cell death, similar to siAKT1-3 in MTG001 and MTG004. Lenalidomide, a recruiter of the E3 ubiquitin ligase Cereblon, conjugated to GDC0068 to form INY-03-041, was used as a negative control for the off-target effects of INY-03-041. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of cell lysates treated with the DMSO control, MK2206 (2.5µM), GDC0068 (1µM), INY-03-041 (500nM), GSK0394 (3µM), GDC0941 (1µM), BYL719 (1µM), siAKT1-3 (50nM) at 22 h, and siAKT1-3 (50nM) for 24 h revealed complete knockdown of P-AKT (Ser473) and total AKT by siAKT1-3 at 24 h, as well as knockdown of P-PRAS40, P-S6 kinase, and P-4EBP1. INY-03-041 displayed a 77% reduction in total AKT compared to the 89% reduction by siAKT1-3. C, Time-course immunoblotting of cell lysates treated with varying concentrations of INY-03-041 demonstrated an incomplete total protein knockdown of individual AKT paralogs. D, Densitometry quantification of time-course immunoblotting found in C.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S1 shows that pharmacological inhibition of AKT has little effect on melanoma cells. Cell confluency assay under pharmacological inhibition. A375, HT144, SK-MEL28, WM793, MTG001, and MTG004 cells were largely resistant to AKT inhibitors MK2206 (2.5 µM) and GDC0068 (1µM) while A375, HT144, WM793, SK-MEL 28 and MTG001 cells were largely sensitive to PI3Kα inhibition by GDC0941 (1µM) (P < 0.001). Error bars indicate standard error of the mean of triplicate wells.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S1 shows that pharmacological inhibition of AKT has little effect on melanoma cells. Cell confluency assay under pharmacological inhibition. A375, HT144, SK-MEL28, WM793, MTG001, and MTG004 cells were largely resistant to AKT inhibitors MK2206 (2.5 µM) and GDC0068 (1µM) while A375, HT144, WM793, SK-MEL 28 and MTG001 cells were largely sensitive to PI3Kα inhibition by GDC0941 (1µM) (P < 0.001). Error bars indicate standard error of the mean of triplicate wells.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S1 shows that pharmacological inhibition of AKT has little effect on melanoma cells. Cell confluency assay under pharmacological inhibition. A375, HT144, SK-MEL28, WM793, MTG001, and MTG004 cells were largely resistant to AKT inhibitors MK2206 (2.5 µM) and GDC0068 (1µM) while A375, HT144, WM793, SK-MEL 28 and MTG001 cells were largely sensitive to PI3Kα inhibition by GDC0941 (1µM) (P < 0.001). Error bars indicate standard error of the mean of triplicate wells.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S1 shows that pharmacological inhibition of AKT has little effect on melanoma cells. Cell confluency assay under pharmacological inhibition. A375, HT144, SK-MEL28, WM793, MTG001, and MTG004 cells were largely resistant to AKT inhibitors MK2206 (2.5 µM) and GDC0068 (1µM) while A375, HT144, WM793, SK-MEL 28 and MTG001 cells were largely sensitive to PI3Kα inhibition by GDC0941 (1µM) (P < 0.001). Error bars indicate standard error of the mean of triplicate wells.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo. Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo. Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.